Zanubrutinib, Bendamustine, and Obinutuzumab for advanced follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and up to 75 years old.
- You must have newly diagnosed, advanced follicular lymphoma (grade I, II, or IIIa).
- You need to have measurable disease (visible on scans or exam).
- Your overall health must be stable enough to carry out daily activities (ECOG 0-2).
- You must have normal organ function (kidney, liver, blood counts) or issues that are acceptable to the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (GCVP) for people with follicular lymphoma who have not had treatment before. The goal is to see if this combination is effective and safe.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
This study is testing a combination of three drugs—zanubrutinib, obinutuzumab, and lenalidomide—as a first treatment for people with a certain type of follicular lymphoma that is considered high-risk. The goal is to see if this combination is safe and effective in controlling the cancer.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.